Anal cancer statistics

Cases

New cases of anal cancer, 2015, UK

Deaths

Deaths from anal cancer, 2016, UK

Survival

Survive anal cancer for 10 or more years, 2009-2013, England

 

Preventable cases

Anal cancer cases are preventable, UK, 2015

 

  • There are around 1,400 new anal cancer cases in the UK every year, that's nearly 4 every day (2013-2015).
  • Anal cancer is not among the 20 most common cancers in the UK, accounting for less than 1% of all new cancer cases (2015).
  • In males in the UK, anal cancer is not among the 20 most common cancers, with around 480 new cases in 2015.
  • In females in the UK, anal cancer is not among the 20 most common cancers, with around 1,000 new cases in 2015.
  • Incidence rates for anal cancer in the UK are highest in people aged 85 to 89 (2013-2015).
  • Since the early 1990s, anal cancer incidence rates have increased by almost two-thirds (63%) in the UK. Rates in males have increased by a fifth (20%), and rates in females have increased by almost two times (99%).
  • Over the last decade, anal cancer incidence rates have increased by around a third (34%) in the UK. Rates in males have remained stable, and rates in females have increased by more than half (52%).
  • Incidence rates for anal cancer are projected to rise by 43% in the UK between 2014 and 2035, to 4 cases per 100,000 people by 2035.
  • Anal cancer in England is more common in people living in the most deprived areas.
  • An estimated 6,700 people who had previously been diagnosed with anal cancer were alive in the UK at the end of 2010.

See more in-depth anal cancer incidence statistics

  • There are around 370 anal cancer deaths in the UK every year, that's around 1 every day (2014-2016).
  • Anal cancer is not among the 20 most common causes of cancer death in the UK, accounting for less than 1% of all cancer deaths (2016).
  • In males in the UK, anal cancer is not among the 20 most common causes of cancer death, with around 160 deaths in 2016.
  • In females in the UK, anal cancer is not among the 20 most common causes of cancer death, with around 240 deaths in 2016.
  • Mortality rates for anal cancer in the UK are highest in people aged 90+ (2014-2016).
  • Since the late 1970s, anal cancer mortality rates have increased by almost three-fifths (57%) in the UK. Rates in males have increased by almost a third (31%), and rates in females have increased by more than four-fifths (82%).
  • Over the last decade, anal cancer mortality rates have increased by more than a fifth (22%) in the UK. Rates in males have increased by a quarter (25%), and rates in females have increased by almost a quarter (23%).
  • Mortality rates for anal cancer are projected to rise by 51% in the UK between 2014 and 2035, to 1 death per 100,000 people by 2035.
  • Anal cancer deaths in England are more common in people living in the most deprived areas.

See more in-depth anal cancer mortality statistics

  • Almost 6 in 10 (57%) people diagnosed with anal cancer in England survive their disease for ten years or more (2009-2013).
  • Almost two-thirds (64%) of people diagnosed with anal cancer in England survive their disease for five years or more (2009-2013).
  • Almost 9 in 10 (86%) people diagnosed with anal cancer in England survive their disease for one year or more (2009-2013).
  • Anal cancer 10-year survival in England is similar in men and women (2009-2013).
  • Anal cancer five-year survival in England is highest for adults diagnosed aged under 50 years old (2009-2013).
  • More than three-quarters of people in England diagnosed with anal cancer aged 15-49 survive their disease for five years or more, compared with around half of people diagnosed aged 70-89 (2009-2013).

See more in-depth anal cancer survival statistics

  • A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
  • 1 in 676 UK males and 1 in 281 UK females will be diagnosed with anal cancer in their lifetime.
  • 91% of anal cancer cases in the UK are preventable.
  • 91% of anal cancer cases in the UK are caused by infections.

See more in-depth anal cancer risk statistics

  • 'GP referral' is the most common route to diagnosing anal cancer.
  • ‘Two-week wait’ standard is met by England, ‘31-day wait’ is met by all countries but Wales, and ‘62-day wait’ is not met by any country for lower gastrointestinal cancers.

See more in-depth anal cancer diagnosis and treatment statistics

Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.

The latest statistics available for anal cancer in the UK are; incidence 2015, mortality 2014, and survival 2009-2013.

The ICD code Open a glossary item for anal cancer is ICD-10 C21.

European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.

Meta-analyses Open a glossary item and systematic reviews Open a glossary item are cited where available, as they provide the best overview of all available research and most take study quality into account. Individual case-control Open a glossary item and cohort studies Open a glossary item are reported where such aggregated data are lacking.

Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2006-2013 due to the small number of cases.

Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Anal cancer is part of the group 'Lower Gastrointestinal cancer' for cancer waiting times data. Codes vary per country but broadly include: small intestine, colon, rectosigmoid junction, rectum, anus and anal canal, other and ill-defined digestive organs, secondary cancers of small intestine, large intestine, rectum, and unspecified digestive organs.

Patient Experience data is for adult patients in England with a primary diagnosis of cancer and who had been in active treatment between September and November 2013 who completed a survey in 2014.

Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN  report.

Last reviewed:

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 2.2 out of 5 based on 17 votes
Thank you!
We've recently made some changes to the site, tell us what you think